DOMH
Price
$1.51
Change
+$0.03 (+2.03%)
Updated
Dec 17 closing price
RGNX
Price
$8.38
Change
-$0.09 (-1.06%)
Updated
Dec 18, 01:44 PM (EDT)
76 days until earnings call
Ad is loading...

DOMH vs RGNX

Header iconDOMH vs RGNX Comparison
Open Charts DOMH vs RGNXBanner chart's image
Dominari Holdings
Price$1.51
Change+$0.03 (+2.03%)
Volume$15.93K
CapitalizationN/A
REGENXBIO
Price$8.38
Change-$0.09 (-1.06%)
Volume$500
CapitalizationN/A
DOMH vs RGNX Comparison Chart
Loading...
DOMH
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RGNX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
DOMH vs. RGNX commentary
Dec 18, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DOMH is a Hold and RGNX is a Hold.

COMPARISON
Comparison
Dec 18, 2024
Stock price -- (DOMH: $1.51 vs. RGNX: $8.47)
Brand notoriety: DOMH and RGNX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: DOMH: 130% vs. RGNX: 135%
Market capitalization -- DOMH: $9.48M vs. RGNX: $419.65M
DOMH [@Biotechnology] is valued at $9.48M. RGNX’s [@Biotechnology] market capitalization is $419.65M. The market cap for tickers in the [@Biotechnology] industry ranges from $486.73B to $0. The average market capitalization across the [@Biotechnology] industry is $2.67B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

DOMH’s FA Score shows that 1 FA rating(s) are green whileRGNX’s FA Score has 1 green FA rating(s).

  • DOMH’s FA Score: 1 green, 4 red.
  • RGNX’s FA Score: 1 green, 4 red.
According to our system of comparison, both DOMH and RGNX are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

DOMH’s TA Score shows that 4 TA indicator(s) are bullish while RGNX’s TA Score has 3 bullish TA indicator(s).

  • DOMH’s TA Score: 4 bullish, 4 bearish.
  • RGNX’s TA Score: 3 bullish, 7 bearish.
According to our system of comparison, DOMH is a better buy in the short-term than RGNX.

Price Growth

DOMH (@Biotechnology) experienced а -9.04% price change this week, while RGNX (@Biotechnology) price change was -13.22% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -4.83%. For the same industry, the average monthly price growth was +1.09%, and the average quarterly price growth was +9.71%.

Reported Earning Dates

DOMH is expected to report earnings on Nov 29, 2024.

RGNX is expected to report earnings on Mar 04, 2025.

Industries' Descriptions

@Biotechnology (-4.83% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
RGNX($420M) has a higher market cap than DOMH($9.48M). DOMH YTD gains are higher at: -41.699 vs. RGNX (-52.813). DOMH has higher annual earnings (EBITDA): -14.1M vs. RGNX (-217.82M). RGNX has more cash in the bank: 255M vs. DOMH (7.17M). DOMH has less debt than RGNX: DOMH (3.15M) vs RGNX (84.1M). RGNX has higher revenues than DOMH: RGNX (84.3M) vs DOMH (12.6M).
DOMHRGNXDOMH / RGNX
Capitalization9.48M420M2%
EBITDA-14.1M-217.82M6%
Gain YTD-41.699-52.81379%
P/E RatioN/AN/A-
Revenue12.6M84.3M15%
Total Cash7.17M255M3%
Total Debt3.15M84.1M4%
FUNDAMENTALS RATINGS
DOMH vs RGNX: Fundamental Ratings
DOMH
RGNX
OUTLOOK RATING
1..100
5959
VALUATION
overvalued / fair valued / undervalued
1..100
9
Undervalued
74
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9798
PRICE GROWTH RATING
1..100
8489
P/E GROWTH RATING
1..100
10027
SEASONALITY SCORE
1..100
85n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

DOMH's Valuation (9) in the null industry is somewhat better than the same rating for RGNX (74) in the Biotechnology industry. This means that DOMH’s stock grew somewhat faster than RGNX’s over the last 12 months.

DOMH's Profit vs Risk Rating (100) in the null industry is in the same range as RGNX (100) in the Biotechnology industry. This means that DOMH’s stock grew similarly to RGNX’s over the last 12 months.

DOMH's SMR Rating (97) in the null industry is in the same range as RGNX (98) in the Biotechnology industry. This means that DOMH’s stock grew similarly to RGNX’s over the last 12 months.

DOMH's Price Growth Rating (84) in the null industry is in the same range as RGNX (89) in the Biotechnology industry. This means that DOMH’s stock grew similarly to RGNX’s over the last 12 months.

RGNX's P/E Growth Rating (27) in the Biotechnology industry is significantly better than the same rating for DOMH (100) in the null industry. This means that RGNX’s stock grew significantly faster than DOMH’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
DOMHRGNX
RSI
ODDS (%)
Bullish Trend 1 day ago
83%
Bearish Trend 6 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
86%
Bullish Trend 1 day ago
73%
Momentum
ODDS (%)
Bearish Trend 1 day ago
88%
Bearish Trend 1 day ago
86%
MACD
ODDS (%)
Bearish Trend 1 day ago
83%
Bearish Trend 1 day ago
90%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
88%
Bearish Trend 1 day ago
85%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
88%
Bearish Trend 1 day ago
86%
Advances
ODDS (%)
Bullish Trend 17 days ago
77%
Bullish Trend 10 days ago
75%
Declines
ODDS (%)
Bearish Trend 3 days ago
89%
Bearish Trend 6 days ago
84%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
89%
Bullish Trend 1 day ago
78%
Aroon
ODDS (%)
Bearish Trend 1 day ago
86%
Bearish Trend 1 day ago
85%
View a ticker or compare two or three
Ad is loading...
DOMH
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RGNX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
MSFEX15.28-0.03
-0.20%
Morgan Stanley Inst Next Gen Em Mkts C
JHGEX13.51-0.09
-0.66%
JHancock Global Equity A
VADCX68.38-0.52
-0.75%
Invesco Equally-Wtd S&P 500 C
FIIAX25.10-0.30
-1.18%
Fidelity Advisor Mid Cap II A
VYSDX10.97-0.17
-1.53%
Voya Small Company R

DOMH and

Correlation & Price change

A.I.dvisor indicates that over the last year, DOMH has been loosely correlated with AXON. These tickers have moved in lockstep 36% of the time. This A.I.-generated data suggests there is some statistical probability that if DOMH jumps, then AXON could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DOMH
1D Price
Change %
DOMH100%
+2.03%
AXON - DOMH
36%
Loosely correlated
-2.09%
ARDX - DOMH
31%
Poorly correlated
-13.54%
MDGL - DOMH
28%
Poorly correlated
-1.58%
ARRY - DOMH
27%
Poorly correlated
+6.01%
RGNX - DOMH
26%
Poorly correlated
-0.82%
More